Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program for Magrolimab

Next Previous
Trial Profile

Expanded Access Program for Magrolimab

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Magrolimab (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Expanded access; Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 13 Feb 2024 Status changed from suspended to completed.
  • 21 Aug 2023 According to a Gilead Sciences media release, the company is working with regulatory authorities to determine next steps to release the partial clinical hold for new patient enrollment
  • 21 Aug 2023 According to a Gilead Sciences media release, screening and enrollment of new study participants under the U.S. investigational new drug application (IND 147229) and U.S. Expanded Access Program will be paused. Patients already enrolled in AML clinical studies may continue to receive treatment and be monitored, according to the current study protocol. Global regulatory authorities and clinical trial investigators involved in the studies have been informed of the FDAs decision.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top